Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$51.80

1.24 (2.45%)

09:22
11/21/16
11/21
09:22
11/21/16
09:22

Kite to present interim results from ZUMA-1 pivotal trial at ASH meeting

Kite Pharma announced that data from the interim analysis of the pivotal ZUMA-1 trial of KTE-C19 in patients with chemorefractory aggressive non-Hodgkin lymphoma have been accepted as an oral late-breaking presentation at the American Society of Hematology, or ASH, 58th Annual Meeting in San Diego, CA, on December 6, 2016. The abstract was one of only six accepted in this category and will be included in the December 1 online issue of Blood. Kite reports that KTE-C19 significantly improved Objective Response Rate in patients with Chemorefractory DLBCL at pre-defined interim analysis. "Outcomes for patients with aggressive NHL depend on whether their disease is sensitive to chemotherapy. The ZUMA-1 study was designed to support registration of KTE-C19 by enrolling a well-defined chemorefractory patient population. We are pleased with the outcome of the study to date and thank the patients and investigators for their participation in the first positive pivotal study in CAR-T therapy," said Jeff Wiezorek, M.D., Senior VP of Clinical Development of Kite.

  • 03

    Dec

  • 03

    Dec

KITE Kite Pharma
$51.80

1.24 (2.45%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.

TODAY'S FREE FLY STORIES

13:15
09/22/17
09/22
13:15
09/22/17
13:15
General news
Oil Action: The weekly Baker-Hughes oil rig count »

Oil Action: The weekly…

13:15
09/22/17
09/22
13:15
09/22/17
13:15
General news
Breaking General news story  »

Dallas Federal Reserve…

TSLA

Tesla

$366.48

-7.43 (-1.99%)

13:10
09/22/17
09/22
13:10
09/22/17
13:10
Options
Heavy trading in Tesla expiring options as the skid continues »

Heavy trading in Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

13:10
09/22/17
09/22
13:10
09/22/17
13:10
General news
Treasury Options Action: bullish call buying in block trade »

Treasury Options Action:…

13:07
09/22/17
09/22
13:07
09/22/17
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 9/22 Baker-Hughes…

RHHBY

Roche

$32.04

0.09 (0.28%)

13:07
09/22/17
09/22
13:07
09/22/17
13:07
Hot Stocks
Roche reports EU approval of Tecentriq in types of lung, bladder cancer »

Roche announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

JUNO

Juno Therapeutics

$41.62

-3.59 (-7.94%)

13:05
09/22/17
09/22
13:05
09/22/17
13:05
Options
Juno Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 22

    Sep

BHGE

Baker Hughes

$36.40

-0.18 (-0.49%)

13:04
09/22/17
09/22
13:04
09/22/17
13:04
Hot Stocks
Baker Hughes reports U.S. rig count down 1 to 935 rigs »

Baker Hughes reports the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 20

    Oct

NVLN

Novelion Therapeutics

13:03
09/22/17
09/22
13:03
09/22/17
13:03
Hot Stocks
Novelion unit Aegerion settles SEC fraud charges for $4.1M »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

, JWN

Nordstrom

$46.62

0.34 (0.73%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Periodicals
Dillard's mentioned in 'vague rumors' about attempting to go-private, Kass says »

Douglas Kass of TheStreet…

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

JWN

Nordstrom

$46.62

0.34 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MMM

3M

$211.18

0.74 (0.35%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Hot Stocks
3M files patent, trademark infringement lawsuit against Thunder Finish »

3M and 3M Innovative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOSL

Fossil

$8.79

-0.21 (-2.33%)

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Options
Fossil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

CMCSA

Comcast

$37.47

0.01 (0.03%)

, FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

12:53
09/22/17
09/22
12:53
09/22/17
12:53
Hot Stocks
Box Office Battle: 'Kingsman' sequel, 'LEGO: Ninjago' look to dethrone 'It' »

After two straight…

CMCSA

Comcast

$37.47

0.01 (0.03%)

FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

VIAB

Viacom

$27.40

-0.32 (-1.15%)

SNE

Sony

$37.43

-0.035 (-0.09%)

DIS

Disney

$98.83

-0.06 (-0.06%)

CMCSK

Comcast

FOXA

21st Century Fox

$26.76

-0.11 (-0.41%)

VIA

Viacom

$38.20

-0.05 (-0.13%)

LGF.B

Lionsgate

$30.36

0.215 (0.71%)

TWX

Time Warner

$102.71

0.22 (0.21%)

LGF.A

Lionsgate

$31.57

0.32 (1.02%)

CBS

CBS

$58.85

0.06 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 22

    Oct

  • 26

    Oct

  • 02

    Nov

AAPL

Apple

$153.39

-2.68 (-1.72%)

, FSLR

First Solar

$48.76

-0.09 (-0.18%)

12:51
09/22/17
09/22
12:51
09/22/17
12:51
General news
On The Fly: Top stock stories at midday »

Stocks on Wall Street…

AAPL

Apple

$153.39

-2.68 (-1.72%)

FSLR

First Solar

$48.76

-0.09 (-0.18%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

W

Wayfair

$75.24

-6.51 (-7.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DDC

Dominion Diamond

$14.19

0.005 (0.04%)

12:49
09/22/17
09/22
12:49
09/22/17
12:49
Hot Stocks
Dominion Diamond receives court approval for plan with The Washington Companies »

Dominion Diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

, VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

12:45
09/22/17
09/22
12:45
09/22/17
12:45
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week inflows…

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

XLF

Financial Select Sector

$25.43

-0.035 (-0.14%)

XLV

Health Care Select Sector SPDR

$81.25

-0.33 (-0.40%)

IWM

iShares Trust Russell 2000 Index Fund

$144.18

0.49 (0.34%)

GLD

SPDR Gold Trust

$123.09

0.41 (0.33%)

VWO

Vanguard FTSE Emerging Markets ETF

$44.17

-0.285 (-0.64%)

TLT

iShares 20+ Year Treasury Bond Fund

$125.84

-0.07 (-0.06%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.33

-0.01 (-0.01%)

IVV

iShares Core S&P 500

$252.18

-0.184 (-0.07%)

VO

Vanguard Mid-Cap Index Fund

$145.73

0.12 (0.08%)

VB

Vanguard Small-Cap Index Fund

$138.57

0.3 (0.22%)

VBK

Vanguard Small-Cap Growth Index Fund

$150.14

0.12 (0.08%)

MDY

SPDR S&P MidCap 400 ETF

$321.08

0.75 (0.23%)

SCHA

Schwab U.S. Small-Cap ETF

$65.69

0.19 (0.29%)

SVXY

ProShares Short VIX Short-Term Futures

$89.22

-0.5004 (-0.56%)

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$93.37

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
09/22/17
09/22
12:45
09/22/17
12:45
General news
Breaking General news story  »

Week of 9/22 Baker-Hughes…

ROK

Rockwell Automation

$177.39

0.06 (0.03%)

12:40
09/22/17
09/22
12:40
09/22/17
12:40
Options
Defensive option play opened in Rockwell »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.35

0.01 (0.01%)

12:30
09/22/17
09/22
12:30
09/22/17
12:30
Options
One week put buyer in the iShares High Yield Bond ETF »

One week put buyer in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$64.11

-0.89 (-1.37%)

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Options
Activision Blizzard call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Conference/Events
FDIC to hold a teleconference »

The FDIC examination…

$NSD

NASDAQ Market Internals

12:17
09/22/17
09/22
12:17
09/22/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
09/22/17
09/22
12:16
09/22/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$144.20

0.51 (0.35%)

12:10
09/22/17
09/22
12:10
09/22/17
12:10
Options
300K puts trade in iShares Small Cap Fund driven by spread trades »

300K puts trade in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.